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≥3 neutropenia occurred in 17.3, 25.4, and 28.6 % of these 
patients, respectively. Multivariate analysis revealed that 
the incidence of grade ≥3 neutropenia was significantly 
greater in the heterozygous and homozygous groups than 
in the wild-type group [odds ratio (OR) 1.67; 95 % confi-
dence interval (CI) 1.16–2.42; p = 0.0060, and OR 2.22; 
95 % CI 1.22–4.02; p = 0.0088, respectively]. Age (OR 
1.77; 95 % CI 1.24–2.53; p = 0.0017), coelomic fluid (OR 
1.84; 95 % CI 1.05–3.25; p = 0.0343), and non-reduction 
in starting dose (OR 1.53; 95 % CI 1.08–2.18; p = 0.0176) 
were also identified as significant risk factors.
Conclusion The risk of neutropenia was higher in the 
heterozygous and homozygous groups at initiation of CPT-
11 treatment. This suggests that when a reduction in dose 
is required in patients harboring two variant alleles, the 
decrease should be approximately 20 %.
Keywords Colorectal · Irinotecan · Neutropenia · 
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Introduction
Irinotecan hydrochloride hydrate (CPT-11), a derivative of 
the antitumor alkaloid camptothecin, inhibits topoisomer-
ase I, and is used to treat various types of tumor, including 
those arising as gastroenterological, lung, or gynecological 
cancers. As such, it forms part of one of the standard chem-
otherapy regimens for colorectal cancer, FOLFIRI, where 
it is used in combination with 5-fluorouracil (5-FU) and 
l-leucovorin (l-LV) [1, 2].
Irinotecan is hydrolyzed to its active metabolite, SN-38, 
by carboxylesterase, primarily in the human liver [3, 4]. 
SN-38 is then metabolized to a non-toxic glucuronide, 
SN-38G, by UDP-glucuronosyltransferase (UGT) 1A1, a 
Abstract 
Background Irinotecan (CPT-11)-induced neutropenia 
is associated with UDP-glucuronosyltransferase (UGT) 
1A1*6 and *28 polymorphisms. This prospective study 
investigated whether using these polymorphisms to adjust 
the initial dose of CPT-11 as part of FOLFIRI treatment in 
colorectal cancer patients might improve safety.
Methods All data were collected by a physician. The rela-
tionship between UGT1A1 polymorphisms and first-cycle 
neutropenia, reasons for treatment discontinuation, and 
time-to-treatment failure were evaluated. Multivariate anal-
ysis was used to assess the risk of neutropenia.
Results A total of 795 patients were divided into wild-
type (*1/*1) (50.1 %), heterozygous (*28/*1, *6/*1) 
(41.1 %), and homozygous (*28/*28, *6/*6, *28/*6) 
(8.which are associated with a decrease in the8 %) groups, 
in which the median starting dose of CPT-11 was 143.0, 
143.0, and 115.0 mg/m2, respectively. First-cycle grade 
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molecular species of UGT in the liver. This metabolite is 
primarily excreted into the bile and transferred to the intes-
tine [5, 6]. Genetic polymorphisms of UGT1A1 include 
UGT1A1*28 and UGT1A1*6, which are associated with 
a decrease in the formation of SN-38G, and thus delayed 
metabolism of SN-38 in the order wild-type, heterozygous, 
and homozygous. As a result, patients with UGT1A1 poly-
morphisms are more susceptible to toxicities such as neu-
tropenia [7–9].
In 2005, the US Food and Drug Administration revised 
the Dosage and Administration section on the labeling of 
CPT-11 as follows: “When administered in combination 
with other agents, or as a single-agent, a reduction in the 
starting dose by at least one level of CAMPTOSAR (brand 
name of CPT-11) should be considered for patients known 
to be homozygous for the UGT1A1*28 allele. However, 
the precise dose reduction in this patient population is not 
known”.
The allele frequency of UGT1A1*28 is lower in 
Asians (8.6–13.0 % in Japanese) than in Caucasians 
(29.5–38.8 %). In contrast, although the frequency of 
the UGT1A1*6 allele is very low in Caucasians, it is 
relatively common in Asians (13.0–17.7 % in Japanese) 
[10], which partly contributes to an increased risk of CPT-
11-induced toxicity in this group. Therefore, in Japan, 
some studies have investigated the relationship between 
UGT1A1 genetic polymorphisms and risk, focusing on the 
following three groups—*1/*1 (wild-type group); *28/*1 
and *6/*1 (heterozygous group); and *28/*28, *6/*6, 
and *28/*6 (homozygous group). Double heterozygo-
sity (*28/*6) was classified as homozygous based on the 
results of other earlier studies [7, 11, 12]. The results of 
one of these earlier clinical studies were inconclusive as 
to the optimum dose of CPT-11 for a homozygous group 
[11].
Approval for testing for UGT1A1*6 and *28 genetic pol-
ymorphisms using the Invader UGT1A1 Molecular Assay 
(Sekisui Medical Co., Ltd, Tokyo, Japan) under national 
insurance was finally given in November 2008 in Japan. 
The test kit then became available in March 2009, making 
this an easy and viable part of therapy in a clinical setting.
The purpose of this prospective study was to investigate 
whether UGT1A1*6 and *28 polymorphisms could be used 
to determine the initial dose level of CPT-11 to improve 
safety in patients receiving FOLFIRI for colorectal cancer.
Patients and methods
Patients
Patients were eligible for inclusion in the present study if 
they met all of the following criteria—CPT-11-naive; no 
evidence of myelosuppression, infectious disease, diarrhea 
(watery stool), intestinal paralysis or obstruction, ascites, 
or jaundice; a diagnosis of colorectal cancer; scheduled to 
receive FOLFIRI; and provided informed consent to partic-
ipate in this study. This study was conducted in accordance 
with Good Post-marketing Study Practice (GPSP) of the 
Ministry of Health, Labour and Welfare, Japan. Approval 
by the Institutional Review Board of each institution was 
not mandatory, as the GPSP does not require such approval 
for post-marketing surveillance.
Classification of UGT1A1 polymorphisms
Three groups were established based on the results of 
testing for UGT1A1*6 and *28 genetic polymorphisms—
wild-type group (*1/*1); heterozygous group (*28/*1 
and *6/*1); and homozygous group (*28/*28, *6/*6, and 
*28/*6). Double heterozygosity (*28/*6) was classified as 
homozygous based on the results of previous studies [7, 11, 
12].
Treatment
FOLFIRI was administered according to a previously 
reported standard schedule in Japan—CPT-11, 5-FU 
(bolus), 5-FU (infusion), and l-LV at 150, 400, 2,400, and 
200 mg/m2, respectively [2, 13]. Because this was a non-
interventional study, the dose level and dosing interval 
were modified at the discretion of the primary physician. 
In this study, a dose reduction was defined as 5 % lower 
(142.5 mg/m2) than the standard dose in Japan (150 mg/
m2). Information on treatment days and dosing levels was 
collected for 1 year after the start of treatment. Time-to-
treatment failure (TTF) was defined as the period of time 
from the start of treatment until the end of treatment due to 
‘progressive disease or tumor death’, ‘adverse event-related 
(side-effect) or treatment-related death’, or ‘withdrawal 
from FOLFIRI’.
Safety evaluation
Adverse events were evaluated according to the Common 
Terminology Criteria for Adverse Events v3.0. The follow-
up period was defined as 1 year after the start of treatment.
Statistical analyses
All analyses were performed using SAS software ver-
sion 9.2 (SAS Institute, Cary, NC, USA). TTF according 
to UGT1A1 genetic polymorphisms was assessed using 
Kaplan–Meier curves, and significance was determined 
using the log-rank test. Using the first cycle as the target, 
the incidence of grade ≥3 neutropenia was analyzed in a 
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multivariate model using a step-down procedure to select 
variables; significance level was set at p = 0.1. The vari-
ables selected were genetic polymorphism, age, sex, East-
ern Cooperative Oncology Group performance status (PS), 
prior chemotherapy, new onset/recurrence, coelomic fluid, 
complications, and starting dose reduction. Differences 
were considered statistically significant when the two-
tailed p value was <0.05.
Results
Baseline characteristics of patients
A total of 823 patients from 210 institutions were initially 
enrolled in the study between April 2009 and March 2011. 
Of these, 795 patients were included in the safety evalua-
tion after excluding two patients not treated with CPT-11, 
24 for whom no data were available, and two who did not 
meet the selection criteria (Fig. 1). Of the 795 patients 
evaluated, 398 (50.1 %) were wild-type, 327 (41.1 %) were 
heterozygous, and 70 (8.8 %) were homozygous accord-
ing to UGT1A1*6 and *28 polymorphisms (Table 1). The 
median ages of the patients in the wild-type, heterozy-
gous, and homozygous groups were 67, 66, and 65 years, 
respectively; 151 (37.9 %), 112 (34.3 %), and 20 (28.6 %) 
patients were aged ≥70 years in each group, respectively. 
No marked imbalance was noted in any other baseline 
characteristics (Table 2).  
CPT‑11 administration
Table 3 shows the starting doses of each drug administered 
as part of FOLFIRI. The dose level of 5-FU did not differ 
among the three groups, but the median starting doses of 
CPT-11 were 143.0, 143.0, and 115.0 mg/m2 in the wild-
type, heterozygous, and homozygous groups, respectively 
(Table 3). A total of 204 patients (50.1 %) in the wild-type 
group, 164 (51.3 %) in the heterozygous group, and 23 
(32.9 %) in the homozygous group received a starting dose 
of CPT-11 of ≥142.5 mg/m2. A bimodal distribution was 
observed in the homozygous group, but not in the wild-type 
or heterozygous groups (Fig. 2).
Fig. 1  Flow chart. A total of 
823 patients tested for UGT1A1 
genetic polymorphisms were 
enrolled in the study. Overall, 
795 patients were included in 
safety evaluation after excluding 




Excluded n = 28 
No treatment n = 2 
Data not available n = 24 





Table 1  Frequencies of UGT1A1 genotype in this study
UGT UDP-glucuronosyltransferase
UGT1A1 genotype n (%)
All patients 795
Wild-type group 398 (50.1)
 *1/*1 398 (50.1)
Heterozygous group 327 (41.1)
 *6/*1 195 (24.6)
 *28/*1 132 (16.6)
Homozygous group 70 (8.8)
 *6/*6 14 (1.8)
 *28/*28 12 (1.5)
 *28/*6 44 (5.5)
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Safety
The incidence of grade ≥3 neutropenia in the first cycle tended 
to increase in the order wild-type < heterozygous < homozy-
gous (17.3, 25.4, 28.6 %, respectively), and this tendency per-
sisted throughout the treatment (44.7, 54.1, and 57.1 %, respec-
tively) (Table 4). The percentages of patients withdrawn from 
treatment were similar for all UGT1A1 genotypes (Table 5). 
Multivariate analysis was performed to identify risk fac-
tors for first-cycle grade ≥3 neutropenia. Heterozygosity 
and homozygosity were identified as significant risk fac-
tors compared with wild-type [heterozygous group: 
p = 0.0060; odds ratio (OR) 1.67; 95 % confidence inter-
val (CI) 1.16–2.42, and homozygous group: p = 0.0088; 
OR 2.22; 95 % CI 1.22–4.02]. Age ≥70 years (p = 0.0017; 
OR 1.77; 95 % CI 1.24–2.53), coelomic fluid (p = 0.0343; 
OR 1.84; 95 % CI 1.05–3.25), and non-reduction in start-
ing dose (p = 0.0176; OR 1.53; 95 % CI 1.08–2.18) were 
also identified as independent significant risk factors 
(Table 6).
Table 2  Baseline characteristics of patients
Characteristics Wild-type (n = 398), n (%) Heterozygous (n = 327), n (%) Homozygous (n = 70), n (%)
Age (years)
 Median 67.0 66.0 65.0
 Range 29–86 35–86 36–81
 <70 247 (62.1) 215 (65.7) 50 (71.4)
 ≥70 151 (37.9) 112 (34.3) 20 (28.6)
Sex
 Male 234 (58.8) 205 (62.7) 41 (58.6)
 Female 164 (41.2) 122 (37.3) 29 (41.4)
Performance status
 0 298 (74.9) 242 (74.0) 48 (68.6)
 1 88 (22.1) 72 (22.0) 22 (31.4)
 ≥2 12 (3.0) 13 (4.0) 0 (−)
Prior chemotherapy
 Absent 73 (18.3) 57 (17.4) 12 (17.1)
 Present 325 (81.7) 270 (82.6) 58 (82.9)
New onset/recurrent
 New onset 201 (50.5) 174 (53.2) 33 (47.1)
 Recurrent 197 (49.5) 153 (46.8) 37 (52.9)
Coelomic fluid
 Absent 374 (94.0) 295 (90.2) 65 (92.9)
 Present 24 (6.0) 32 (9.8) 5 (7.1)
Complications
 Absent 250 (62.8) 193 (59.0) 48 (68.6)
 Present 148 (37.2) 134 (41.0) 22 (31.4)
Table 3  State of clinical use
CPT-11 irinotecan, 5-FU 5-fluorouracil
Wild-type (n = 398) Heterozygous (n = 327) Homozygous (n = 70)
Starting dose (mg/m2)
 CPT-11, median (range) 143.0 (56–185) 143.0 (23–181) 115.0 (41–180)
 Bolus 5-FU, median (range) 384.0 (0–796) 380.0 (0–800) 383.5 (0–517)
 Infusional 5-FU, median  
(range)
2327.0 (538–2542) 2312.0 (178–2830) 2299.0 (0–2469)
Distribution of starting CPT-11 dose
 <142.5 mg/m2 (%) 194 (48.7) 163 (49.8) 47 (67.1)
 ≥142.5 mg/m2 (%) 204 (51.3) 164 (50.2) 23 (32.9)
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Efficacy
Figure 3 shows the Kaplan–Meier curves obtained for TTF 
according to UGT1A1 genetic polymorphism. No signifi-
cant difference was observed among the UGT1A1 genetic 
polymorphisms [wild-type group vs heterozygous or 
homozygous group: p = 0.7390; hazard ratio (HR) 1.025; 
95 % CI 0.888–1.183, and wild-type or heterozygous group 
vs homozygous group: p = 0.1582; HR 1.197; 95 % CI 
0.931–1.540]. The median TTF was 161.5 (95 % CI 142.0–
183.0), 165.0 (95 % CI 148.0–177.0), and 136.0 (95 % 
CI 106.0–177.0) days in the wild-type, heterozygous, and 
homozygous groups, respectively (Table 4).
The present results indicated little difference in effect 
of each polymorphism on TTF, regardless of starting dose 
(data not shown).
Discussion
The goal of the present study was to investigate whether 
UGT1A1*6 and *28 polymorphisms could be used to deter-
mine the initial dose level of CPT-11 to improve safety in 
patients receiving FOLFIRI for colorectal cancer. These results 
comprise the largest published prospective analysis to date.
The multivariate analysis revealed that the incidence of 
neutropenia increased significantly in those groups har-
boring one or more alleles compared with the wild-type 
group—the heterozygous and homozygous groups showed 
a 1.67-fold and 2.22-fold increase in risk of grade ≥3 neu-
tropenia, respectively. Minami et al. reported that neutro-
penia was associated with homozygosity for UGT1A1*6 or 
*28 [9]. However, Hoskins et al. [14] and Hu et al. [15] 
reported inconsistent results from meta-analyses of the 
relationship between homozygosity for UGT1A1*28 and 
neutropenia in patients treated with CPT-11 at a starting 
dose of <150 mg/m2, and no definitive relationship was 
therefore demonstrated. The results of the present study, 
albeit non-interventional, support the findings of Minami 
et al. and Hu et al. Moreover, the present study was based 
on an analysis of data from a single set of 795 patients, 
and therefore comprises a larger sample size than those 
in the above-mentioned studies. Satho et al. [11] and 
Hazama et al. [16] found that the pharmacokinetics of 
SN 38 were higher in patients harboring one variant allele 
than in those who were not. Moreover, in the Satho study, 
there was a significant correlation between an increase 
















































































































Fig. 2  Distribution of starting dose of CPT-11 in a wild-type 
(n = 398), b heterozygous (n = 327), and c homozygous groups 
(n = 70)
◂
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pharmacokinetics of SN38. Taken together, these results 
suggest that the initial dose of CPT-11 should be consid-
ered with care in patients homozygous or heterozygous for 
UGT1A1 in clinical practice in Japan. However, previous 
studies reported that the risk for those who were heterozy-
gous was small, indicating the need for further evaluation 
of clinical information on UGT1A1*6 and *28 heterozy-
gous groups in future studies.
The observed OR for the risk of neutropenia in the 
homozygous group compared with the wild-type group 
(2.22) was lower than (5.21–8.63) reported in previous 
studies [11, 17]. Hoskins et al. [14] reported that the risk 
of neutropenia abated with a decrease in the dose of CPT-
11. In their study, the OR was 1.80 at lower doses, which 
represented no significant difference between homozygous 
and wild-type or heterozygous individuals, similar to the 
findings in the present study.
In addition to UGT1A1 polymorphisms, the present 
study also identified age ≥70 years, coelomic fluid, and 
non-reduction in starting dose as risk factors for grade ≥3 
neutropenia. The relationship between age and risk of neu-
tropenia remains unexplained, although older patients are 
generally more likely to experience adverse events, prob-
ably because of age-related changes in pharmacokinetics or 
pharmacodynamics and an increased prevalence of chronic 
diseases. The trend observed in the present study is in line 
with the results of an earlier study showing that CPT-11 
monotherapy was associated with a higher risk of grade ≥3 
neutropenia in the elderly [18]. The relationship between 
coelomic fluid and risk of neutropenia also remains poorly 
understood, although an increased risk of CPT-11-related 
leukopenia in pleural effusion and massive ascites was 
reported [19]. We believe that the retention of coelomic 
fluid decreases intestinal peristalsis, thereby delaying 
excretion of CPT-11 and increasing toxicity. In addition, 
there appears to be an association between coelomic fluid 
and peritoneal dissemination. This suggests that the dis-
ease is likely to be at a more advanced stage by the time 
treatment is initiated in patients with coelomic fluid. Taken 
together with the results from earlier studies, the present 
results suggest that patient age and presence of coelomic 
fluid should also be taken into consideration when planning 
treatment in a clinical setting.
In the present study, the starting dose of CPT-11 was 
reduced in approximately 67 % of patients in the homozy-
gous group, but not in the wild-type or heterozygous 
groups, resulting in a median starting dose that was approx-
imately 20 % lower in the homozygous group. A previous 
study [11] investigating dose levels in Japanese patients 
Table 4  Median TTF 
and reasons for treatment 
discontinuation
TTF time-to-treatment failure, CI confidence interval, FOLFIRI l-leucovorin, 5-fluorouracil, and irinotecan
Wild-type (n = 398) Heterozygous (n = 327) Homozygous (n = 70)
TTF
 Median 161.5 165.0 136.0
 95 % CI 142.0–183.0 148.0–177.0 106.0–177.0
Reasons for discontinuing FOLFIRI
 Progressive disease (%) 183 (46.0) 169 (51.7) 33 (47.1)
 Adverse events (%) 59 (14.8) 52 (15.9) 10 (14.3)
 Withdrawal of FOLFIRI (%) 75 (18.8) 53 (16.2) 14 (20.0)
Table 5  Association between UGT1A1 genotype and irinotecan tox-
icities
Toxicities Wild-type 
(n = 398), n (%)
Heterozygous 
(n = 327), n (%)
Homozygous
(n = 70), n (%)
First-cycle neutropenia
 Grade ≥1 209 (52.5) 199 (60.9) 42 (60.0)
 Grade ≥3 69 (17.3) 83 (25.4) 20 (28.6)
Neutropenia
 Grade ≥1 311 (78.1) 266 (81.3) 55 (78.6)
 Grade ≥3 178 (44.7) 177 (54.1) 40 (57.1)
All adverse events
 Grade ≥1 383 (96.2) 321 (98.2) 68 (97.1)
 Grade ≥3 229 (57.5) 223 (68.2) 48 (68.6)
Table 6  Multivariate predictors of treatment-related grade ≥3 neu-
tropenia




OR (95 % CI) p value*
UGT1A1 genotype (wild-type vs het-
erozygous)
1.67 1.16–2.42 0.0060
UGT1A1 genotype (wild-type vs 
homozygous)
2.22 1.22–4.02 0.0088
Age (years) (<70 vs ≥70) 1.77 1.24–2.53 0.0017
Sex (male vs female) 1.38 0.97–1.95 0.0726
Coelomic fluid (absent vs present) 1.84 1.05–3.25 0.0343
Starting dose reduction (reduction vs 
non-reduction)
1.53 1.08–2.18 0.0176
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according to UGT1A1*6 and *28 polymorphisms demon-
strated the safety of 150 mg/m2 in wild-type and heterozy-
gous groups; however, no recommended dose was identi-
fied for homozygous patients because of a large individual 
variation in pharmacokinetics.
The results of the present study indicate that testing for 
UGT1A1*6 and *28 genetic polymorphisms could be use-
ful in determining the appropriate starting dose of CPT-11 
in clinical practice.
An analysis of treatment duration in relation to UGT1A1 
genetic polymorphisms revealed that TTF was similar 
between the wild-type, heterozygous, and homozygous 
groups, as were the reasons for treatment discontinua-
tion. Blood drug concentrations were not measured in the 
current study, but the metabolism of SN-38 is delayed in 
individuals homozygous for UGT1A1 polymorphisms [9, 
20]. In the present study, the dose level in the homozy-
gous group was reduced, allowing the pharmacokinetics of 
SN-38 to be maintained without compromising its antitu-
mor efficacy and avoiding serious adverse events requiring 
treatment discontinuation; therefore, there was no effect on 
the treatment duration. However, caution should be taken in 
reducing the dose, as it may increase the risk of ineffective 
treatment.
In conclusion, the present results revealed that patients 
harboring one or more alleles had a higher risk of neutro-
penia at initiation of treatment, indicating the importance 
of testing for UGT1A1 genetic polymorphisms before com-
mencing therapy. These results also suggest that when a 
reduction in dose is required in patients harboring two vari-
ant alleles, the decrease should be approximately 20 %.
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